GLP-1

• Health Canada approves country’s 1st generic version of Ozempic

  The injectable semaglutide medication is manufactured by Dr. Reddy's Laboratories in India and is approved for the once-weekly treatment of Type 2 diabetes in adults.

  Health

  Apr 28
  
• U.S. FDA approves Eli Lilly’s GLP-1 oral weight-loss pill

  The U.S. FDA said the drug was approved within 50 days of the company filing for approval, one of the fastest approval times for any drug.

  Health

  Apr 1
  
• Advertisement
• Could GLP-1 drugs help your mental health? New study finds a link

  Semaglutide, the active ingredient in GLP-1 drugs, was associated with a lower risk of worsening mental health, a study published in Lancet Psychiatry found.

  Health

  Mar 20
• Advertisement
• Novo Nordisk says generic Ozempic, Wegovy will slow sales in Canada

  Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.

  Health

  Feb 4
• Health Canada approves 1st GLP-1 daily pill. Here’s who can take it

  The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.

  Canada

  Jan 12
• Many regain weight after stopping GLP-1 drugs, data shows. Here’s why

  People on average regain weight at a rate of 0.4 kg/month after they stopped taking their weight loss medications, a review of 63 trials covering over 9,000 individuals showed.

  Health

  Jan 8